PAINCHEK LTD — Capital/Financing Update 2024

Feb 14, 2024

==> picture [182 x 42] intentionally omitted <==

15 February 2024

The Manager Company Announcements Office ASX Limited

20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Notice under Section 7(f)(ii) of ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547

PainChek Ltd (ACN 146 035 127) (ASX:PCK) ( Company ) refers to its announcement on 14 February 2024 in respect of the opportunity for eligible shareholders to purchase up to $30,000 worth of new fully paid ordinary shares in the Company under a share purchase plan ( SPP ).

The SPP will be offered in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 . It is a condition of that instrument that the Company issue this notice before the SPP offer is made. The SPP will open (and the SPP offer will be made) at 9.00 a.m. (Sydney time) on 16 February 2024.

Shares ) under a share purchase plan without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) ( Corpora�ons Act ).

Accordingly, the Company gives the ASX (as the relevant market operator) notice that:

1. The Company will make offers to issue shares under the SPP without disclosure to investors under Part 6D.2 of the Corporations Act;

2. This notice is being given in accordance with section 7(f)(ii) of ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 ;

3. As at the date of this notice, the Company has complied with:

4. (a) the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and

5. (b) section 674 and 674A of the Corporations Act; and

ABN 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000

P: +61 1800 098 809 E: info@painchek.com W: painchek.com

1. As at the date of this notice, there is no excluded information (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) in relation to the Company which is required to be disclosed to investors generally.

For the purpose of ASX Listing Rule 15.5, the Board of directors has authorised this announcement to be released.

Natalie Climo

Company Secretary PainChek Ltd

About PainChek

PainChek[®] is the world’s first regulatory-cleared medical device for the assessment of pain, enabling bestpractice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek[® ] app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek[®] Analytics.

Globally, PainChek[®] has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek[® ] has contracts with over 1,000 aged care facilities, with more than 4,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek[®] , facilities can:

• Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias

• Streamline the pain assessment process for time-poor carers, with access to the PainChek[®] tool, the NRS, pain trends, and charting in one solution

• Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place

• Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the Journal of Alzheimer’s Disease. An article in BMC Geriatrics

ABN 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000

P: +61 1800 098 809 E: info@painchek.com W: painchek.com

indicates that PainChek[® ] is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found here.

PainChek[® ] has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated PainChek[®] Infant app identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: https://painchek.com

ABN 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000

P: +61 1800 098 809 E: info@painchek.com W: painchek.com